Bristol Myers Squibb Company $BMY Stock Bought by Alps Advisors Inc.

Key Points

• Alps Advisors increased its Bristol Myers Squibb stake by 13.2% in the third quarter, adding 73,806 shares to hold 632,070 shares valued at about $39.4 million. Institutional investors and hedge funds own 76.41% of the stock.
• Bristol Myers Squibb beat quarterly expectations, reporting adjusted earnings of $1.35 per share and $13.07 billion in revenue; revenue rose 6.9% year over year, while EPS fell from $1.63 a year earlier.
• Recent pipeline developments include positive pediatric Phase 3 results for Camzyos and an expanded neuroscience AI alliance. Separately, coverage has raised concerns about future blood-thinner sales declines and debt pressure on dividend sustainability.

Alps Advisors Inc. boosted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 13.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 632,070 shares of the biopharmaceutical company's stock after buying an additional 73,806 shares during the quarter. Alps Advisors Inc.'s holdings in Bristol Myers Squibb were worth $39,441,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Primecap Management Co. CA acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $980,862,000. BlackRock Inc. lifted its position in shares of Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp increased its position in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Finally, Caisse de depot et placement du Quebec purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $243,646,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Analyst Upgrades and Downgrades

BMY has been the topic of several recent research reports. Roth Capital started coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price target on the stock. Sanford C. Bernstein restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 13th. Argus upgraded Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price target on the stock in a report on Wednesday, August 5th. Rothschild & Co Redburn upped their target price on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a "neutral" rating in a research note on Thursday, October 8th. Finally, HSBC reissued a "hold" rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of "Hold" and an average target price of $65.46.

Bristol Myers Squibb Stock Down 1.5%

Shares of BMY opened at $62.20 on Friday. The company has a 50-day moving average price of $62.34 and a two-hundred day moving average price of $60.11. The stock has a market cap of $127.15 billion, a price-to-earnings ratio of 10.12, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 12 month low of $45.26 and a 12 month high of $68.64. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion for the quarter, compared to analysts' expectations of $12.72 billion. During the same quarter last year, the business earned $1.63 EPS. The company's quarterly revenue was up 6.9% compared to the same quarter last year. Equities analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.88%.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the business's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the transaction, the director owned 30,279 shares in the company, valued at $1,916,963.49. The trade was a 11.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company's medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.